RevenanasBook a free audit

M&A

Karyopharm files Chapter 11, names Ayrmid as lead bidder in planned merger

Biotech

M&A

Key Facts

Signal Type

M&A

Industry

Biotech

Companies

Karyopharm Therapeutics, Ayrmid, Gamida Cell, Incyte

Date

What Happened

Karyopharm Therapeutics, the Massachusetts-based maker of multiple myeloma drug Xpovio, filed for Chapter 11 bankruptcy as part of a plan to merge with Irish hematology biotech Ayrmid. Ayrmid — parent company of blood cancer biotech Gamida Cell — is named lead bidder in a court-supervised sale of Karyopharm's assets, though the terms of its offer were not disclosed and the merger is not final.

The bidding structure, if approved by the court, allows other parties to submit competing proposals, an approach Karyopharm says is designed to maximize value for stakeholders. The transaction is expected to close in the first quarter of 2027. Karyopharm also secured commitments for up to $55 million in debtor-in-possession financing from its existing lenders, subject to court approval, which it says combined with Xpovio revenue will fund operations through the Chapter 11 process.

Who Is Affected

Karyopharm retains its commercial product Xpovio and its multiple myeloma and myelofibrosis pipeline through the restructuring. Xpovio posted $30.8 million in second-quarter sales, up slightly from $29.7 million a year earlier, but annual sales have stayed flat between $112 million and $115 million since 2023. The company has already cut staff by 20% in 2023 and another 20% last year.

Ayrmid brings two FDA-approved products — cell therapy Omisirge and Aphexda, approved in 2023 for stem cell retrieval in multiple myeloma — and its chairman and CEO Joe Wiley cited "complementary portfolios, established commercial capabilities and a shared commitment" to hematology. Incyte is also in the frame: in August, Karyopharm applied for FDA accelerated approval of Xpovio in combination with Incyte's Jakafi for myelofibrosis patients.

Market Impact

The filing caps a difficult year that included a Phase 3 myelofibrosis miss in March, the FDA's May rescission of Xpovio's accelerated approval in relapsed or refractory DLBCL, and a failed endometrial cancer Phase 3 in July that sent shares down more than 68%. That sequence, plus a cash runway leadership said in August covered only another month, is what forced the sale process.

  • Restructuring advisory, legal and claims-management work is live now, gated by court approval of the bidding procedures and the DIP facility.
  • Commercial continuity for Xpovio — a $112M–$115M annual franchise — creates transition and operations work regardless of who wins the auction.
  • Ayrmid's integration of Karyopharm's myeloma and myelofibrosis programs into an existing commercial hematology portfolio implies IT, data and sales-ops migration.
  • The open bidding structure means additional suitors can surface before the Q1 2027 close, expanding the pool of potential buyers.

What to Watch

Court approval of the bidding procedures and the $55 million DIP facility is the first gate — without it, the timeline and the financing both slip. Watch for competing bids ahead of the auction, since Karyopharm explicitly structured the process to invite them, and for any change to the Q1 2027 close target.

On the commercial side, track the FDA accelerated approval filing for Xpovio plus Jakafi in myelofibrosis and whether Xpovio revenue holds near $30 million per quarter through the Chapter 11. Any further pipeline setback or prescriber disruption would weaken the asset case Ayrmid is underwriting.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner